Nicholas J. Newman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicholas J. Newman has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Courtney Veltri
University Hospitals of Cleveland (Cleveland Medical Center)
3 shared publications - Leila S. Hojat
Emory University School of Medicine
3 shared publications - Alexis P Lee
Environmental and Social Sustainability, University of Utah Health , Salt Lake City, Utah
1 shared publication Amanda G Woods
Pharmacy Services, University of Utah Health , Salt Lake City, Utah
1 shared publication- Anil J. Chakravorty
Case Western Reserve University School of Medicine
1 shared publication - Brigid M. Wilson
Geriatric Research Education and Clinical Center (GRECC), VA Northeast Ohio Healthcare System
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e325
Implementation of an automated methicillin-resistant Staphylococcus aureus polymerase chain reaction screening intervention to guide discontinuation of vancomycin for pneumonia
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogen commonly implicated in pneumonia for which vancomycin is often used to cover empirically. Our study examined the impact of a pharmacy-based automatic MRSA polymerase chain reaction (PCR) nares intervention. Methods: We included patients prescribed vancomycin for pneumonia and defined three cohorts: pre-intervention (Cohort 1), post-test implementation (Cohort 2), and post-test implementation with electronic medical record (EMR) enhancements and active stewardship involvement (Cohort 3). The primary outcome was total duration of vancomycin treatment. We performed a desirability of outcome ranking with response adjusted for duration of antibiotic risk (DOOR/RADAR) analysis to prioritize clinical outcomes including adverse events, escalation of care, and death. Results: The median duration of vancomycin therapy decreased between Cohorts 1 and 2 (55 versus 47 hours, p = 0.15), with a greater decrease detected among the subset of Cohort 2 patients from whom the PCR test was actually collected (42 hours, p = 0.035). Duration of therapy was lowest in Cohort 3 (22.3 hours, p < 0.001). In the DOOR/RADAR analysis, no meaningful difference in clinical outcomes was detected between Cohorts 1 and 2 ( p = 0.55). Cohort 3 had substantially better ranked outcomes when compared to Cohorts 1 and 2 ( p < 0.001). Conclusion: Vancomycin treatment duration was shorter in patients after a pharmacy-directed, EMR-based MRSA PCR intervention was implemented, with a greater response after implementation of additional EMR enhancements and active stewardship involvement, improving test collection rate and result response. This study will help inform future interventions pairing automated EMR-based interventions with stewardship team efforts.
- 1 December 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e325
Open AccessImplementation of an automated methicillin-resistant Staphylococcus aureus polymerase chain reaction screening intervention to guide discontinuation of vancomycin for pneumonia
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogen commonly implicated in pneumonia for which vancomycin is often used to cover empirically. Our study examined the impact of a pharmacy-based automatic MRSA polymerase chain reaction (PCR) nares intervention. Methods: We included patients prescribed vancomycin for pneumonia and defined three cohorts: pre-intervention (Cohort 1), post-test implementation (Cohort 2), and post-test implementation with electronic medical record (EMR) enhancements and active stewardship involvement (Cohort 3). The primary outcome was total duration of vancomycin treatment. We performed a desirability of outcome ranking with response adjusted for duration of antibiotic risk (DOOR/RADAR) analysis to prioritize clinical outcomes including adverse events, escalation of care, and death. Results: The median duration of vancomycin therapy decreased between Cohorts 1 and 2 (55 versus 47 hours, p = 0.15), with a greater decrease detected among the subset of Cohort 2 patients from whom the PCR test was actually collected (42 hours, p = 0.035). Duration of therapy was lowest in Cohort 3 (22.3 hours, p < 0.001). In the DOOR/RADAR analysis, no meaningful difference in clinical outcomes was detected between Cohorts 1 and 2 ( p = 0.55). Cohort 3 had substantially better ranked outcomes when compared to Cohorts 1 and 2 ( p < 0.001). Conclusion: Vancomycin treatment duration was shorter in patients after a pharmacy-directed, EMR-based MRSA PCR intervention was implemented, with a greater response after implementation of additional EMR enhancements and active stewardship involvement, improving test collection rate and result response. This study will help inform future interventions pairing automated EMR-based interventions with stewardship team efforts.
- Open Access
- 14 October 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e263
Estimated greenhouse gas emissions associated with unnecessary intravenous antimicrobials administered in the hospital setting
Background: Healthcare has deleterious impacts on the environment through production of massive amounts of waste leading to generation of greenhouse gas (GHG) emissions. Single-use materials used for preparation and administration of intravenous (IV) medications are a large component of hospital waste. Transitioning medications from the IV-to-oral (PO) route, called switch therapy, may be a means of decreasing unnecessary waste and associated emissions arising from hospital care. Methods: This was a retrospective cohort study involving adult patients receiving IV antimicrobials with a highly bioavailable PO equivalent at a large academic medical center. For a randomly selected subset of patients, the mean number of IV days of therapy (DOT) for which PO therapy could have been administered based on our institution’s policy was determined for each antimicrobial. This proportion was applied to the full cohort to estimate the total unnecessary IV DOT. A GHG emissions estimation tool was used to estimate the emissions generated from the excess antimicrobials. Results: During the study period, 15,037 IV DOT were administered, of which 9,694 DOT (64%) were estimated to be unnecessary. This was estimated to have generated 2,049 kilograms of total waste and 0.353 metric tons of carbon dioxide equivalents, equivalent to 904 miles driven. Conclusions: Optimizing IV-to-PO antimicrobial switch policies may be an effective way to decrease hospital environmental impact through reduction of single-use supply waste and associated emissions. Future work should prioritize evaluating other potential antimicrobial stewardship interventions as a means to reduce GHG emissions.
- 14 October 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e263
Open AccessEstimated greenhouse gas emissions associated with unnecessary intravenous antimicrobials administered in the hospital setting
Background: Healthcare has deleterious impacts on the environment through production of massive amounts of waste leading to generation of greenhouse gas (GHG) emissions. Single-use materials used for preparation and administration of intravenous (IV) medications are a large component of hospital waste. Transitioning medications from the IV-to-oral (PO) route, called switch therapy, may be a means of decreasing unnecessary waste and associated emissions arising from hospital care. Methods: This was a retrospective cohort study involving adult patients receiving IV antimicrobials with a highly bioavailable PO equivalent at a large academic medical center. For a randomly selected subset of patients, the mean number of IV days of therapy (DOT) for which PO therapy could have been administered based on our institution’s policy was determined for each antimicrobial. This proportion was applied to the full cohort to estimate the total unnecessary IV DOT. A GHG emissions estimation tool was used to estimate the emissions generated from the excess antimicrobials. Results: During the study period, 15,037 IV DOT were administered, of which 9,694 DOT (64%) were estimated to be unnecessary. This was estimated to have generated 2,049 kilograms of total waste and 0.353 metric tons of carbon dioxide equivalents, equivalent to 904 miles driven. Conclusions: Optimizing IV-to-PO antimicrobial switch policies may be an effective way to decrease hospital environmental impact through reduction of single-use supply waste and associated emissions. Future work should prioritize evaluating other potential antimicrobial stewardship interventions as a means to reduce GHG emissions.
- Open Access
- 29 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10) , ofaf308
Development of a Novel Carbon Emissions Estimation Tool for Disposable Waste Associated With Antimicrobial Packaging, Preparation, and Administration in the Hospital Setting
Background: Addressing climate change is one of the most pressing needs of society. The One Health approach recognizes the importance of antimicrobials at the intersection between humans, animals, and the environment and advocates for mitigation of antimicrobial overuse, primarily as a means of preventing antimicrobial resistance. Antimicrobial use additionally contributes to climate change through consumption of single-use disposable products used for packaging, drug preparation, and intravenous drug administration, which in turn generates greenhouse gas (GHG) emissions when disposed. Methods: We estimated the GHG emissions associated with intravenous antimicrobials given in the hospital setting, initially performing the data collection in a large academic hospital in Cleveland, Ohio, and validating the data in another large academic hospital in Salt Lake City, Utah. For each antimicrobial agent, we identified all disposable packaging, preparation, and administration materials. Materials were weighed and classified by type, and total GHG emissions measured in carbon dioxide equivalents were calculated using emission factors defined by the U.S. Environmental Protection Agency. Results: Results were summarized in tables listing GHG emissions per dose per antimicrobial agent, and a calculator tool was created in spreadsheet format to accommodate antimicrobial use data collected by hospital antimicrobial stewardship programs. Conclusions: We developed a novel tool for estimating GHG emissions associated with single-use waste generated from IV antimicrobial packaging, preparation, and administration in the hospital setting. This tool can be used by antimicrobial stewardship programs to assess their institutions’ GHG emissions and provide another stewardship value measure quantifying avoided GHG emissions with antimicrobial optimization strategies.
- 29 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10) , ofaf308
Open AccessDevelopment of a Novel Carbon Emissions Estimation Tool for Disposable Waste Associated With Antimicrobial Packaging, Preparation, and Administration in the Hospital Setting
Background: Addressing climate change is one of the most pressing needs of society. The One Health approach recognizes the importance of antimicrobials at the intersection between humans, animals, and the environment and advocates for mitigation of antimicrobial overuse, primarily as a means of preventing antimicrobial resistance. Antimicrobial use additionally contributes to climate change through consumption of single-use disposable products used for packaging, drug preparation, and intravenous drug administration, which in turn generates greenhouse gas (GHG) emissions when disposed. Methods: We estimated the GHG emissions associated with intravenous antimicrobials given in the hospital setting, initially performing the data collection in a large academic hospital in Cleveland, Ohio, and validating the data in another large academic hospital in Salt Lake City, Utah. For each antimicrobial agent, we identified all disposable packaging, preparation, and administration materials. Materials were weighed and classified by type, and total GHG emissions measured in carbon dioxide equivalents were calculated using emission factors defined by the U.S. Environmental Protection Agency. Results: Results were summarized in tables listing GHG emissions per dose per antimicrobial agent, and a calculator tool was created in spreadsheet format to accommodate antimicrobial use data collected by hospital antimicrobial stewardship programs. Conclusions: We developed a novel tool for estimating GHG emissions associated with single-use waste generated from IV antimicrobial packaging, preparation, and administration in the hospital setting. This tool can be used by antimicrobial stewardship programs to assess their institutions’ GHG emissions and provide another stewardship value measure quantifying avoided GHG emissions with antimicrobial optimization strategies.